Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Will vote with CA on this one.
They never mentioned or addressed why they said fw was a up value for fundraising when it was not. This was one of ca points.
All I want is share price to rise and effect m true value. As now up for sale, will be interesting to see what value market puts on it if any!
It was an impressive move with HUR , CRS seem on the ball .
Looks like a good move. Interesting comment there about an accidental press release from FW stating they had exceeded revenue forecasts by four times.
Crystal Amber Fund requisitions General Meeting of Allied Minds plc to propose the removal of the Chairman, Harry Rein, as a director.
https://www.investegate.co.uk/crystal-amber-fund/rns/crystal-amber-requisitions-gm-of-allied-minds-plc/202202181515351800C/
Agreed. Comms is very poor. Waiting on Aurora launch for orbital giving an additional revenue stream. Bc are busy but website not updated regularly. They are also Rev producing.
https://24activenews.com/2021/10/05/hyspeciq-and-bridgecomm-join-together-for-hi-speed-optical-downlinks/
https://spacenews.com/bridgecomm-space-micro-deal-2021/
https://news.satnews.com/2021/09/09/optical-inter-satellite-links-now-offered-by-bridgecomm-to-customers/
A great example of the lack of communication/effort is that Spark Insights is listed as a portfolio company on the AlliedMinds web site. That was sold 2 1/2 months ago , well more accurately it was swapped for Concirrus stock. Concirrus now own Spark. So why aren't Concirrus listed? Why isn't there an RNS espousing the exciting opportunity with Concirrus? In the spirit of providing information via this forum here's their website: https://www.concirrus.ai/ - impressive client list and exciting product that has the potential to disrupt the market.
Pablo - take a look at the portfolio's web sites. My take on where they are:
1. Federated Wireless - completely revamped their web site - looks very slick - looks the part, and in fact appears very encouraging. In line with expectations that this one will come good during 2022.
2. BridgeComm - out of date links, no new news since 2020. I see there's news not reported on their web site e.g.
https://www.businesswire.com/news/home/20210401005281/en/BridgeComm-Will-Commence-Targeted-Customer-Demos-of-Ultra-Broadband-Speeds-Surpassing-100GB-per-Second
Disappointing..... however that link of their latest news looks encouraging. In my opinion BridgeComm are nowhere near an IPO in 2022 - based on appearances.
3. Orbital Sidekick - again a very professional and slick web site and the last news is last summer's launch. There was meant to be a launch of a further 6 (?) Aurora satellites in early 2022. But there's no mention of this.
This video/interview is impressive:
https://orbitalsidekick.com/orbital-sidekicks-aurora-satellite-uses-technology-towards-a-sustainable-future/
It's the sort of business you want to succeed but again I don't see any tangible evidence of a 2022 IPO so my guess would be this is going to be 2023 earliest.
AlliedMinds web site? RNS updates? No! Poor communication - you get more updates from following this forum!
News on federated must be soon as well as bridgecomm. Looking for a substantial uplift on both. Last raise in 2019 fed valued at 26p to ALM and BC 8p. Both now revenue producing and market leaders.
I think the problem is the issue that CA is having. Read his last report. His Fund lost a vote and looks like will have to wind up and he has said that the 2 funds that hold 30% of his fund have large shorts on alm and de la rue and r using his fund as a hedge to their position. CA have said they will respond within next few weeks about what they r going to do.
I presume the share price will continue to drift until we get a further update in relation to Federated Wireless IPO or another funding round. It would be nice to have an actual timeline from the ALM Board without giving sensitive information away or is that too much to ask for? Something like we need to tick these boxes before FW can list would be sufficient.
Disappointed to learn of the 12.8% Fully-Diluted interest in OcuTerra Therapeutics but probably for the best as ALM Board wants to wind down holdings. Post-Money Valuation is $49.5 million and our interest is valued at around $6.3m now.
ALM’s holding in occuterra is 12.8%. We did not participate in the funding round hence the huge dilution. Harry Rein wrote the company off valuing it at 0 despite his “experience in life sciences “. Subsequently Occuterra raised 35mill and attracted big hitters in the life sciences market.
This is all in the half yearly report.
Feds last fund raise valued at 215 mill largely pre revenue. They now have double digit revenue and looking for high double digit next year. New funding round imminent and will be disappointing to see a new fund raise if less than 500mill based on current and projected near term revs.
Yes communication is shocking
We don't know the details and should have had an RNS advising of the fund raise.
If there was dilution to our holding or if ALM participated in the fund raise we should be told via RNS.
What was is the dilution to ALM for the funds raised? Did they take part in the fund raising? U would have though a rns would have been made about this!
As you can see below OcuTerra has raised a further $35m in addition to the $14.6m it secued earlier this year. This bodes extremely well for our 54.16% holding in the company.
“OTT166 offers potential significant benefit for patients, caregivers and eye care practitioners by providing a non-invasive treatment option for people suffering from diabetic retinopathy,” said Carl Regillo, M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University. “In addition to fulfilling the unmet need of offering a non-invasive treatment option, which would be acceptable to more patients, OTT166 can potentially be administered earlier than eye injections, which may prevent severe disease progression and functional vision loss. I am compelled by the early data and believe that OTT166 has the potential to transform the standard of care for patients with this disease.”
OcuTerra Expands Scientific Advisory Board
OcuTerra also announced the appointment of Paul M. Karpecki, OD, FAAO to its Scientific Advisory Board.
“We are delighted to have Dr. Karpecki join our Scientific Advisory Board as we move forward with the development of OTT166,” said David Tanzer, M.D., ophthalmologist and Chief Medical Officer of OcuTerra. “Paul is a leader and pioneer in the eye care field, and his commitment to innovation aligns with our mission to change the standard of care for the treatment of diabetic eye disease.”
“I am thrilled to join the Scientific Advisory Board of OcuTerra and represent the voice of Doctors of Optometry who manage over 70% of all patients with diabetic retinopathy in the U.S.,” said Dr. Karpecki. “Working closely with my fellow advisors from the retina and anterior segment ophthalmology communities, I am very excited about the development of OTT166, a topical drug candidate to prevent diabetic retinopathy disease progression and loss of visual function.”
Dr. Karpecki received his Doctor of Optometry degree from Indiana University and completed a Durrie Fellowship in Medical Cornea/Refractive Surgery in Kansas City in affiliation with the Pennsylvania College of Optometry. In 2017-2018 he completed a full year preceptorship in advanced retinal disease at Retina Associates of Kentucky, one of the top 20 retina practices in the country. He currently serves as Director of Cornea and External Disease for the Kentucky Eye Institute in Lexington KY. Dr. Karpecki is the Chief Clinical Editor for Review of Optometry, the most read journal in the profession, and chairman of the New Technology and Treatment Conferences. He is Medical Director for KEPLR Vision and Director of Cornea and External Disease for the Center for Sight in Carmel, IN. He was appointed to the Delphi International Society at Wilmer Johns Hopkins which included the top 25 dry eye experts in the world and co-chair for the previous two Tear Film and Ocular Surface Society Symposia. Dr. Karpecki served on the DEWS II Diagnostic Methodology Committee. He is also an Associate Professor at the Kentucky College of Optometry in Pikeville, KY and serves on the board of the charitable organization Optometry
OcuTerra Raises $35 Million Series B Financing
OTT166 DR-EAM Phase 2 Study Expected to Commence Early 2022
Paul Karpecki, OD, FAAO, Appointed to Scientific Advisory Board
November 09, 2021 06:00 AM Eastern Standard Time
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of care of “watch and wait” does not prevent or control the progression of disease, today announced the final close of a $35 million Series B financing. Proceeds will support the DR-EAM (Diabetic Retinopathy - Early Active Management) Phase 2 study of OTT166 in patients with moderate to severe non-proliferative and mild proliferative diabetic retinopathy. The study is expected to commence early next year.
Phase 1b clinical trials of OTT166 eye drops in patients with diabetic retinopathy and wet AMD have demonstrated safety, tolerability and clear clinical evidence of biological activity. OTT166 is a novel small molecule selective integrin inhibitor that OcuTerra has purpose engineered to have the required physiochemical characteristics to be able to reach the retina from eye drop application. Designed to be administered by the patient at home, OTT166 has the potential to dramatically change the treatment paradigm by enabling earlier, non-invasive treatment to preserve vision and prevent progression, thereby delaying or completely eliminating the need for intravitreal injections.
“OcuTerra is well-positioned to transform the treatment landscape for diabetic retinopathy, the leading cause of vision loss and blindness in working age adults in America,” said Kerrie Brady, Chief Executive Officer of OcuTerra. “The current standard of care for these patients is ‘watch and wait’ until vision deteriorates due to diabetic macular edema or the disease progresses to the proliferative form, at which point medically intensive and invasive eye injections and/or laser treatments are instituted. Our mission is to transform the standard of care with OTT166 to offer a non-invasive, easy to administer, effective treatment that can be prescribed earlier in the disease course by a broader range of eye care providers to avoid sight threatening complications, stop disease progression and potentially avoid invasive treatments. We look forward to evaluating OTT166 in Phase 2 trials beginning early next year.”
CONT...
Yes Echo1, Federated Wireless has great potential. I don't think ALM will be able to mess the listing up, Harry Rein sits on the Board along with 7 other very capable individuals. I've got a lot of time for CEO Iyad Tarazi too. FW has 8 very capable investors who would want the highest return they can achieve. If they wanted to make life easier for themselves, they could probably flog the company to the likes of Amazon / Google now for profit or they could wait some time to sell for multiples.
HigherRating, I think ST was basing his opinion on the research note from Edison. Spin Memory was valued at $180m, ALM fully diluted share was being valued at $60m+. Luckily for ALM shareholders, the company is diversified and we could still make decent returns from the likes of FW. Its also worth noting that OcuTerra Therapeutics was given a ZERO valuation previously but secured $14.6m in funding earlier this year, ALM have a 54.16% holding in the company.
Yes I quite agree Maj
I've long held the belief that FW will become bigger than all of ALM's investments combined.
I'm only disappointed that I can't my average of 36p down a little further at the present time.
I wonder how ALM will monetise the IPO. Assuming they'll do a good job of it isn't a given . . . .
The post the board put out failed to mention 4x expected revenue for federated. “ The last year has seen 4 times the company’s expected revenue growth, its customer and partner base expand rapidly into new verticals, and the number of active CBRS devices grow to more than 70,000. https://www.globenewswire.com/news-release/2021/11/05/2328739/0/en/UPDATE-Federated-Wireless-Accelerates-Leadership-in-Shared-Spectrum-Market.html
It feels to me Federated Wireless are getting ready for an IPO, Simon Thompson was talking of this a few months back and predicted an $1bn+ valuation.
Allied Minds ownership is 43.11% and fully-diluted ownership is 36.61%.
The SP should be 100p+ just based on the above, even if FW have a $500m valuation the SP should be more than double the current price. I think investor appetite is low due to past board performance but the market will be surprised when the company is listed IMO.
Long History of Market Leadership
The CBRS market leader, Federated Wireless was the first to launch a commercial spectrum access system (SAS) and environmental sensing capability (ESC) network, which have been deployed across several vertical markets with numerous use cases. The company currently has more than 200 customers with 70k+ connected devices across the United States and overseas. Its customer base includes electric co-ops; large interstate gas and electric; oil refineries; commercial and federal enterprises, and tier one Mobile Network Operators (MNOs), including Verizon Wireless nationwide CBRS 4G and 5G. Additional deployments include tier one cable operators and tower companies; and more than 100 Wireless Internet Service Providers (WISPs).
"The last 12 months have seen strong growth in interest, traction and innovation from Federated Wireless, the FCC and other players in the market as we work together to build what promises to be the single most significant contributor to US 5G leadership," said Tarazi. "I would like to thank our customers, our partners and our investors as we head into what promises to be another record-shattering year for CBRS, shared spectrum and private 5G."
2/2
Federated Wireless Accelerates Leadership in Shared Spectrum Market
Significant milestones reached in past 12 months, including high-profile vertical deployments and reaching more than 200 customers plus 70,000 active CBRS devices, illustrate solid traction and bright future for the entire market
ARLINGTON, Va., Nov. 04, 2021 - Federated Wireless , shared spectrum and private wireless network pioneer, has driven a number of significant advancements in the past 12 months. The company currently has more than 200 customers, with 70,000 devices deployed, which together indicate strong momentum for the entire market segment. These include the launch of the secondary CBRS spectrum market via its Spectrum Exchange; significant deployments of a dedicated CBRS network for IoT research at Fort Carson, Colo. and another for modernization of the Marine Corps Logistics Command warehouse operations in Albany, Ga.; along with deployment of the first CBRS networks in Puerto Rico and the U.S Virgin Islands, delivering service to the region's Wireless Internet Service Providers (WISPs) and Mobile Network Operators (MNOs). The last year has seen its customer and partner base expand rapidly into new verticals and the number of active CBRS devices grow to more than 70,000.
"The CBRS market is growing fast and helping answer the need for additional spectrum across a variety of use cases," said Kevin Hasley, CEO of RootMetrics. "And it is having an impact at a critical juncture. Few could have anticipated just how quickly and steadily device densities, application bandwidth needs, and rural connectivity requirements have accelerated over the last few years. Our testing of mobile operators shows that CBRS brings significant performance improvements for carriers who have used it to enhance the spectrum they have available in markets across the US. Ultimately, CBRS will help improve connectivity not just for service providers but stands to bring benefits to consumers, businesses, and the industry itself."
"We are extremely pleased with both the growth of the sector and Federated Wireless' leadership in it and are proud to have realized the potential of shared spectrum, the technology and the company," said Iyad Tarazi, CEO of Federated Wireless. "We think this is only the tip of the iceberg as we continue to lead the industry forward with innovative thinking, a rapidly growing ecosystem and a strong base of customers spanning multiple industries."
1/2